Dilip Sanghavi led Sun Pharma reported a net loss of Rs 2,227.38 crore in the most recent quarter, compared to a profit of Rs 848 crore a year ago. The company’s revenue for the quarter increased by 11% year on year to Rs 9,386.08 crore. According to one poll, the company was predicted to earn Rs 1,707 crore in profit on revenue of Rs 9,576 crore.
Exceptional items totaled Rs 3,935.75 crore in the quarter, compared to Rs 672.81 crore the previous year. Settlements and provisions pertaining to Taro Pharmaceuticals and Ranbaxy are among the notable items.
“FY22 was a solid year in terms of topline and EBITDA growth. Despite increased prices, all of our geographies have had double-digit growth, and profitability has improved. “The specialised business continues to grow substantially, with global Ilumya sales increasing by 81 percent to US$315 million in FY22,” stated Dilip Shanghvi, the company’s Managing Director.
“Our India business continues to outperform the market, resulting in a higher market share.” “We will continue to focus on increasing all of our companies, extending our global speciality business, and improving operational efficiencies,” Shanghvi stated.
Also Read: Sun Pharma Acquires Uractiv Portfolio